Literature DB >> 7886770

Can malaria chemoprophylaxis be restricted to first pregnancies?

A M Greenwood1, C Menendez, P L Alonso, S Jaffar, P Langerock, S Lulat, J Todd, B M'Boge, N Francis, B M Greenwood.   

Abstract

The harmful effects of malaria are most pronounced during first pregnancies and chemoprophylaxis is most effective when given at this time. However, restriction of chemoprophylaxis to first pregnancies might lead to enhanced susceptibility to malaria during second pregnancies. We have investigated this possibility by studying the outcome of second pregnancies in 165 Gambian women who had received either malaria chemoprophylaxis with Maloprim or placebo during their first pregnancy. Many of these primigravidae did not present until the third trimester of pregnancy so that some are likely to have experienced a malaria infection before they started medication. The prevalence of malaria infection of the blood and of the placenta during second pregnancies was similar in women who had received chemoprophylaxis during their first pregnancy and in those who had not, and the mean birth weights of babies born to women in each group were almost identical. Thus, in areas where the epidemiology of malaria is similar to that of The Gambia and where most women present relatively late in pregnancy, it may be possible to restrict malaria chemoprophylaxis to first pregnancies with consequent savings in cost and a reduction in drug pressure on Plasmodium falciparum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7886770     DOI: 10.1016/0035-9203(94)90228-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  Knowledge and utilization of malaria control measures by pregnant and newly delivered mothers in Ibadan, Nigeria.

Authors:  A Oladokun; R E Oladokun; O A Adesina
Journal:  Afr Health Sci       Date:  2011-12       Impact factor: 0.927

Review 2.  The safety of antimalarial drugs in pregnancy.

Authors:  P A Phillips-Howard; D Wood
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

3.  Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria.

Authors:  Trine Staalsoe; Caroline E Shulman; Edgar K Dorman; Ken Kawuondo; Kevin Marsh; Lars Hviid
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  Antibody to P. falciparum in pregnancy varies with intermittent preventive treatment regime and bed net use.

Authors:  Elizabeth H Aitken; Bernard Mbewe; Mari Luntamo; Teija Kulmala; James G Beeson; Per Ashorn; Stephen J Rogerson
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

5.  Knowledge and utilization of intermittent preventive treatment for malaria among pregnant women attending antenatal clinics in primary health care centers in rural southwest, Nigeria: a cross-sectional study.

Authors:  Stella O Akinleye; Catherine O Falade; Ikeoluwapo O Ajayi
Journal:  BMC Pregnancy Childbirth       Date:  2009-07-09       Impact factor: 3.007

Review 6.  Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas.

Authors:  Valérie Briand; Gilles Cottrell; Achille Massougbodji; Michel Cot
Journal:  Malar J       Date:  2007-12-04       Impact factor: 2.979

7.  Cellular immune response to Plasmodium falciparum after pregnancy is related to previous placental infection and parity.

Authors:  Nadine Fievet; Germaine Tami; Bertrand Maubert; Marlène Moussa; Ian K Shaw; Michel Cot; Anthony A Holder; Gérard Chaouat; Philippe Deloron
Journal:  Malar J       Date:  2002-11-26       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.